Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia

Medical Hypotheses

Volumn 80, Issue 1, 2013, Pages 83-93

  Bogen, Kenneth T ^a  

^a EXPONENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADAPTIVE HYPERPLASIA; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CELL POPULATION; HUMAN; HYPERPLASIA; INFECTION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MECHANICS; MUTATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; STRESS; WOUND;

CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HUMANS; HYPERPLASIA; MICRORNAS; MODELS, BIOLOGICAL; MUTATION; MYOCYTES, SMOOTH MUSCLE; STRESS, PHYSIOLOGICAL;

EID: 84870897089     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.10.017     Document Type: Article

References (279)

1. Hanahan D., Weingberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Armitage P., Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 1957, 11:161-169.
3. Whitemore A., Keller J.B. Quantitative theories of carcinogenesis. SIAM Rev 1978, 20:1-30.
4. Moolgavkar S.H., Venzon D.J. Two-event models for carcinogenesis: Incidence curves for childhood and adult tumors. Math Biosci 1979, 47:55-77.
5. Moolgavkar S.H., Knudson A.G. Mutation and cancer: a model for human carcinogenesis. JNCI 1981, 66:1037-1052.
6. Moolgavkar S.H. Model for human carcinogenesis: Action of environmental agents. Environ Health Perspect 1983, 50:285-291.
7. Moolgavkar S.H., Dewanji A., Venzon D.J. A stochastic two-stage model for cancer risk assessment. 1. The hazard function and the probability of tumor. Risk Anal 1988, 8:383-392.
8. Bogen K.T. Cell proliferation kinetics and multistage cancer risk models. J Natl Cancer Inst 1989, 81:267-277.
9. Ames B.N., Gold L.S. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 1990, 31:970-971.
10. Cohen S.M., Ellwien L.B. Cell proliferation in carcinogenesis. Science 1990, 247:1007-1011.
11. Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res 1990, 50:7415-7421.
12. Takabe W., Niki E., Uchida K., Yamada S., Satoh K., Noguchi N. Oxidative stress promotes the development of transformation: involvement of a potent mutagenic lipid peroxidation product, acrolein. Carcinogenesis 2001, 22(6):935-941.
13. Zhang H., Kamendulis L.M., Jiang J., Xu Y., Klaunig J.E. Acrylonitrile-induced morphological transformation in Syrian hamster embryo cells. Carcinogenesis 2000, 21(4):727-733.
14. Pu X., Kamendulis L.M., Klaunig J.E. Acrylonitrile-induced oxidative DNA damage in rat astrocytes. Environ Mol Mutagen 2006, 47(8):631-638.
15. Kitchin K.T., Ahmad S. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol Lett 2003, 137(1):3-13.
16. Liu L., Trimarchi J.R., Paula Navarro P., Blasco M.A., Keefe D.L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis. J Biol Chem 2003, 278(34):31998-33200.
17. Ahsan H., Chen Y., Kibriya M.G., Islam M.N., Slavkovich V.N., Graziano J.H., et al. Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett 2003, 201(1):57-65.
18. An Y., Gaob Z., Wang, Yang S., Liang J., Feng Y., et al. Immunohistochemical analysis of oxidative DNA damage in arsenic-related human skin samples from arsenic-contaminated area of China. Cancer Lett 2004, 214(1):11-18.
19. He X., Chen M.G., Lin G.X., Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2×Keap1×Cul3 complex and recruiting Nrf2×Maf to the antioxidant response element enhancer. J Biol Chem 2006, 281(33):23620-23631.
20. Eblina K.E., Bowen M.E., Cromey D.W., Bredfeldt T.G., Mash E.A., Lau S.S., et al. Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. Toxicol Appl Pharmacol 2006, 217(1):7-14.
21. Broaddus V.C., Yang L., Scavo L.M., Ernst J.D., Boylan A.M. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996, 98(9):2050-2059.
22. Broaddus V.C., Yang L., Scabo L.M., Ernst J.D., Boylan A.M. Crocidolite asbestos induces apoptosis of pleural mesothelial cells: role of reactive oxygen species and poly(ADP-ribosyl) polymerase. Environ Health Perspect 1997, 105(Suppl. 5):1147-1152.
23. Yang H., Bocchetta M., Kroczynska B., Elmishad A.G., Chen Y., Liu Z., et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006, 103(27):10397-10402.
24. Winn L.M. Homologous recombination initiated by benzene metabolites: a potential role of oxidative stress. Toxicol Sci 2003, 72:143-149.
25. Butterworth B.E., Templin M.V., Borghoff S.J., Conolly R.B., Kedderis G.L., Wolf D.C. The role of regenerative cell proliferation in chloroform-induced cancer. Toxicol Lett 1995, 82-83:23-26.
26. Beddowes E.J., Faux S.P., Chipman J.K. Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology 2003, 187(2-3):101-115.
27. Eastmond D.A. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: a case study involving carbon tetrachloride. Environ Mol Mutagen 2008, 49(2):132-141.
28. Kamendulis L.M., Zhang H., Wang Y., Klaunig J.E. Morphological transformation and oxidative stress induced by cyanide in Syrian Hamster Embryo (SHE) cells. Toxicol Sci 2002, 68:437-443.
29. Park S., Won Seok Kim, Un Jung Choi, Sang Uk Han, Yong Seok Kim, Young Bae Kim, et al. Amelioration of oxidative stress with ensuing inflammation contributes to chemoprevention of H. pylori-associated gastric carcinogenesis. Antiox Redox Signal 2004, 6(3):549-560.
30. Correa P. Does Helicobacter pylori cause gastric cancer via oxidative stress?. Biol Chem 2006, 387(4):361-364.
31. Whysner J., Williams G.M. 2,3,7,8-Tetrachlorodibenzo-p-dioxin mechanistic data and risk assessment: gene regulation, cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 1996, 71(1-2):193-223.
32. Yoshida R., Ogawa Y. Oxidative stress induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin: an application of oxidative stress markers to cancer risk assessment of dioxins. Ind Health 2007, 38(1):5-14.
33. Bhat H.K., Calaf G., Hei T.K., Loya T., Vadgama J.V. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci USA 2003, 100(7):3913-3918.
34. Kwon Y.-W., Shugo Ueda S., Ueno M., Yodoi J., Masutani H. Mechanism of p53-dependent apoptosis induced by 3-methylcholanthrene: involvement of p53 phosphorylation and p38 MAPK. J Biol Chem 2002, 277(3):1837-1844.
35. Kasprzak K.S. The role of oxidative damage in metal carcinogenicity. Chem Res Toxicol 1991, 4:604-615.
36. Chen C.Y., Huang Y.L., Lin T.H. Association between oxidative stress and cytokine production in nickel-treated rats. Arch Biochem Biophys 1998, 356:127-132.
37. Kalinich J.F., Emond C.A., Dalton T.K., Mog S.R., Coleman G.D., Kordell J.E., et al. Embedded weapons grade tungsten alloy shrapnel rapidly induces metastatic high grade rhabdomyosarcomas in F344 rats. Environ Health Perspect 2005, 113(6):729-734.
38. Nunoshiba T., Demple B. Potent intracellular oxidative stress exerted by the carcinogen 4-nitroquinoline-N-oxide. Cancer Res 1993, 53:3250-3252.
39. Ahotupa M., Bussacchini-Griot V., Béréziat J.-C., Camus A.-M., Bartsch H. Rapid oxidative stress induced by N-nitrosamines. Biochem Biophys Res Commun 1987, 146(3):1047-1054.
40. Demizu Y., Sasaki R., Trachootham D., Pelicano H., Colacino J.A., Liu J., et al. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid Redox Signal 2008, 10(5):951-961.
41. Delker D., Hatch G., Allen J., Crissman B., George M., Geter D., et al. Molecular biomarkers of oxidative stress associated with bromate carcinogenicity. Toxicology 2006, 221(2-3):158-165.
42. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Ann Rev Pharmacol Toxicol 2003, 44:239-267.
43. Mori K., Shibanuma M., Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 2004, 64:7464-7472.
44. Toyokuni S. Novel aspects of oxidative stress-associated carcinogenesis. Antioxid Redox Signal 2006, 8(7-8):1373-1377.
45. Reliene R., Schiestl R.H. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 2006, 27(2):240-244.
46. Richie J.P., Komninou D., Albino A.P. Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice. Int J Oncol 2007, 30(6):1539-1543.
47. Federico A., Morgillo F., Tuccillo C., Ciardiello F., Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007, 121(11):2381-2386.
48. Soory M. Oxidative stress induced mechanisms in the progression of periodontal diseases and cancer: a common approach to redox homeostasis?. Cancer 2010, 2:670-692.
49. Yu Y.-H., Liao C.-C., Hsu W.-H., Chen H.-J., Liao W.-C., Muo C.-H., et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol 2010, 6(1):32-37.
50. Rosen M.P., Anwar W.A., Ward A.J. Inflammation, chromosomal instability, and cancer-the schistosomiasis model. Cancer Res 1994, 54(Suppl.):1929s-1933s.
51. Balkwill F., Mantovani A. Inflammation and cancer-back to Virchow?. Lancet 2001, 357(9255):539-545.
52. Coussens L.M., Werb Z. Inflammatory cells and cancer-think different!. J Exp Med 2001, 193(6):F23-F26.
53. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Ann Rev Pathol Mech Dis 2006, 1:119-150.
54. Schwartsburd P.M. Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control. Cancer Metastasis Rev 2003, 22(1):95-102.
55. Li A.G., Lu S.-L., Zhang M.-X., Deng C., Wang X.-J. Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res 2004, 64(21):7836-7845.
56. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66(2):605-612.
57. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007, 101(4):937-949.
58. Lawrence T. Inflammation and cancer: a failure of resolution?. Trends Pharmacol Sci 2007, 28(4):162-165.
59. Lin W.-W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117(5):1175-1183.
60. Perwez Hussain S., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121(11):2373-2380.
61. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19(2):209-216.
62. Valinluck V., Sowers L.C. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res 2007, 67(12):5583-5586.
63. Weinberg R.A. Mechanisms of malignant progression. Carcinogenesis 2008, 29(6):1092-1095.
64. Jarnicki A., Putoczki T., Ernst M. Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?. Cell Div 2010, 5:14. http://www.celldiv.com/content/5/1/14 [accessed 26.12.2010].
65. National Cancer Institute (NCI). NCI think tanks in cancer biology: inflammation and cancer think tank. NCI, Washington, DC. [accessed 26.12.2010]. http://www.cancer.gov/think-tanks-cancer-biology/.
66. Schetter A.J., Heegaard N.H.H., Harris C.C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31(1):37-49.
67. Sodir N.M., Brown Swigart L., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011, 25:907-916.
68. Stenbäck F., Peto R., Shubik P. Initiation and promotion at different ages and doses in 2200 mice. III. Linear extrapolation from high doses may underestimate low-dose tumour risks. Br J Cancer 1981, 44:24-34.
69. Sieweke M.H., Thompson N.L., Sporn M.B., Bissell M.J. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-β. Science 1990, 248(4963):1656-1660.
70. Dvorak H.F. Tumors: wounds that do not heal. N Engl J Med 1986, 315(26):1650-1659.
71. Jacobs T.W., Byrne C., Colditz G., Connolly J.L., Schnitt S.J. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med 1999, 340:430-436.
72. Chmielowiec J., Borowiak M., Morkel M., Stradal T., Munz B., Werner S., et al. C-Met is essential for wound healing in the skin. J Cell Biol 2007, 177(1):151-162.
73. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
74. Wajed S.A., Laird P.W., DeMeester T.R. DNA methylation: an alternative pathway to cancer. Ann Surg 2001, 234(1):10-20.
75. Feinberg A.P., Cui H., Ohlsson R. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 2002, 12(5):389-398.
76. Esteller M., Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002, 196(1):1-7.
77. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4(2):143-153.
78. Herman J.G. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol 2005, 70:329-333.
79. Hoffmann M.J., Schulz W.A. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005, 83(3):296-321.
80. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006, 2006(310):251-274.
81. Yamada Y., Watanabe M., Yamanaka M., Hirokawa Y., Suzuki H., Takagi A., et al. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. Cancer Sci 2003, 94(6):536-539.
82. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006, 12(3 Pt. 1):989-995.
83. Saito Y., Jones P.A. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006, 5(19):2220-2222.
84. Brueckner B., Stresemann C., Kuner R., Mund C., Musch T., Meister M., et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007, 67(4):1419-1423.
85. Kanai Y., Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007, 28(12):2434-2442.
86. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setién F., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 67(4):1424-1429.
87. Akhtar-Zaidi B., Cowper-Sal-lari R., Corradin O., Saiakhova A., Bartels C.F., Balasubramanian D., et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 2012, 336(6082):736-739.
88. Aldaz C.M., Conti C.J., Klein-Szanto A.J., Slaga T.J. Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc Natl Acad Sci USA 1987, 84(7):2029-2032.
89. Li R., Yerganian G., Duesberg P., Kraemer A., Willer A., Rausch C., et al. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci USA 1997, 94(26):14506-14511.
90. Duesberg P., Rausch C., Rasnik D., Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998, 95(23):13692-13697.
91. Rasnick D., Duesberg P.H. How aneuploidy affects metabolic control and causes cancer. Biochem J 1999, 340(Pt. 3):621-630.
92. Duesberg P., Li R., Rasnick D., Rausch C., Willer A., Kraemer A., et al. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet 2000, 119(2):83-93.
93. Duesberg P., Stindl R., Hehlmann R. Explaining the high mutation rates of cancer cells todrug and multidrug resistance by chromosomereassortments that are catalyzed by aneuploidy. PNAS 2000, 97(26):14295-14300.
94. Duesberg P., Stindl R., Li R., Hehlmann R., Rasnick D. Aneuploidy versus gene mutation as cause of cancer. Curr Sci 2001, 81(5):490-500.
95. Duesberg P., Stindl R., Hehlmann R. Origin of multidrug resistance in cells with andwithout multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. PNAS 2001, 98(20):11283-11288.
96. Fabarius A., Willer A., Yerganian G., Hehlmann R., Duesberg P. Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. PNAS 2002, 99(10):6778-6783.
97. Krämer A., Neben K., Ho A.D. Centrosome replication, genomic instability and cancer. Leukemia 2002, 16:767-775.
98. Duesberg P., Li R. Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle 2003, 2(3):20-210.
99. Duesberg P., Fabarius A., Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic in stability of neoplastic and preneoplastic cells. IUBMB Life 2004, 56(2):65-81.
100. Duesberg P., Li R., Fabarius A., Hehlmann R. The chromosomal basis of cancer. Cell Oncol 2005, 27(5-6):293-318.
101. Li R., Hehlmann R., Sachs R., Duesberg P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genetics Cytogenet 2005, 163(1):44-56.
102. Hanks S., Rahman N. Aneuploidy-cancer predisposition syndromes: a new link between the mitotic spindle checkpoint and cancer. Cell Cycle 2005, 4(2):225-227.
103. Stindl R. Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. Med Hypoth 2008, 71(1):126-140.
104. Sheltzer J.M., Blank H.M., Pfau S.J., Tange Y., George B., Humpton T.J., et al. Aneuploidy drives genomic instability in yeast. Science 2011, 333(6045):1026-1030.
105. Solomon D.A., Kim T., Diaz-Martinez L.A., Fair J., Elkahloun A.G., Harris B.T., et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011, 333(6045):1039-1043.
106. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99:15524-15529.
107. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancer. Proc Natl Acad Sci USA 2004, 101(9):2999-3004.
108. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
109. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66(15):7390-7394.
110. Dalmay T., Edwards D.R. MicroRNAs and the hallmarks of cancer. Oncogene 2006, 25(46):6170-6175.
111. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12(12):580-587.
112. Hwang H.-W., Mendell J.T. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94(6):776-780.
113. Stahlhut Espinosa C.E., Slack F.J. The role of microRNAs in cancer. Yale J Biol Med 2006, 79(3-4):131-140.
114. Thomson J.M., Newman M., Parker J.S., Morin-Kensicki E.M., Wright T., Hammond S.M. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006, 20(16):2202-2207.
115. Dutta K.K., Zhong Y., Liu Y.-T., Yamada T., Akatsuka S., Hu Q., et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 2007, 98(12):1845.
116. Cho W.C.S. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007, 6:60. 10.1186/1476-4598-6-60.
117. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007, 67(18):8433-8438.
118. Goga A., Benz C. Anti-oncomir suppression of tumor phenotypes. Mol Interv 2007, 7(4):199-202.
119. Hagan J.P., Croce C.M. MicroRNAs in carcinogenesis. Cytogenet Genome Res 2007, 118(2-4):252-259.
120. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447(7148):1130-1134.
121. Kumar M.S., Lu J., Mercer K.L., Golub T.R., Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39(5):673-677.
122. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163):682-688.
123. Mayr C., Hemann M.T., Bartel D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315(5818):1576-1579.
124. Osada H., Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007, 28(1):2-12.
125. Shell S., Park S.-M., Radjabi A.R., Schickel R., Kistner E.O., Jewell D.A., et al. Let-7 expression defines two differentiation stages of cancer. PNAS 2007, 104(27):11400-11405.
126. Zhang B.H., Pan X.P., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302(1):1-12.
127. Pogribny I.P. MicroRNA dysregulation during chemical carcinogenesis. Epigenomics 2009, 1(2):281-290.
128. Giglio S., Andrea Vecchione A. Role of microRNAs in the molecular diagnosis of cancer. J Nucl Acid Invest 2010, 1(1):1e4. http://dx.doi.org/10.4081/jnai.2010.e4.
129. Palmer R.D., Murray M.J., Saini H.K., van Dongen S., Abreu-Goodger C., Muralidhar B., et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res 2010, 70(7):2911-2923.
130. Shih I.-M., Zhou W., Goodman S.N., Lengauer C., Kinzler K.W., Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 2001, 61(3):818-822.
131. Bueno M.J., Malumbres M. MicroRNAs and the cell cycle. Biochimica et Biophysica Acta 2011, 1812(5):592-601.
132. Kawasaki H., Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004, 431:211-217.
133. Han L., Witmer P.D., Casey E., Valle D., Sukumar S. DNA methylation regulates microRNA expression. Cancer Biol Ther 2007, 6(8):1284-1288.
134. Weber B., Stresemann C., Brueckner B., Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007, 6(9):1001-1005.
135. Fabbri M., Calin G.A. Epigenetics and miRNAs in human cancer. Adv Genet 2010, 70:87-99.
136. Iorio M.V., Piovan C., Croce C.M. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010, 1799(10-12):694-701.
137. Huppi K., Volfovsky N., Mackiewicz M., Runfola T., Jones T.L., Martin S.E., et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007, 17(1):65-73.
138. Barlogie B., Drewinko B., Schumann J., Göhde W., Dosik G., Latreille J., et al. Cellular DNA content as a marker of neoplasia in man. Am J Med 1980, 69(2):195-203.
139. Chen R.B. Flow cytometric analysis of benign and malignant tumors of the oral and maxillofacial region. J Oral Maxillofac Surg 1989, 47(6):596-606.
140. Bañez E.I., Krishnan B., Ansari M.Q., Carraway N.P., McBride R.A. False aneuploidy in benign tumors with a high lymphocyte content: a study of Warthin's tumor and benign thymoma. Hum Pathol 1992, 23(11):1244-1251.
141. Eto H., Toriyama K., Tsuda N., Tagawa Y., Itakura H. Flow cytometric DNA analysis of vascular soft tissue tumors, including African endemic-type Kaposi's sarcoma. Hum Pathol 1992, 23(9):1055-1060.
142. Pinto A.E., Fonseca I., Soares J. The clinical relevance of ploidy and S-phase fraction determination in salivary gland tumors: a flow cytometric study of 97 cases. Cancer 1999, 85(2):273-281.
143. Castro P., Sansonetty F., Soares P., Dias A., Sobrinho-Simões M. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern. Virchows Arch 2001, 438(4):336-342.
144. Gerstner A.O.H., Müller A.-K., Machlitt J., Tárnok A., Tannapfel A., Weber A., et al. Slide-based cytometry for predicting malignancy in solid salivary gland tumors by fine needle aspirate biopsies. Cytometry B (Clin Cytom) 2003, 53B(1):20-25.
145. Du T.T., Zamore P.D. MicroPrimer: the biogenesis and function of microRNA. Development 2006, 132(21):4653-4662.
146. Djuranovic S., Nahvi A., Green R. A parsimonious model for gene regulation by miRNAs. Science 2011, 331(6017):550-553.
147. Ambros V., Bartel B., Bartel D.P., Burge C.B., Carrington J.C., Chen X., et al. A uniform system for microRNA annotation. RNA 2003, 9(3):277-279.
148. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
149. Bohnsack M.T., Czaplinski K., Görlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10(2):185-191.
150. Zeng Y., Cullen B.R. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res 2004, 32(16):4776-4785.
151. Kim V.N. MicroRNA biogenesis: coordinated coping and dicing. Nat Rev Mol Cell Biol 2005, 6(5):376-385.
152. George A.D., Tenenbaum S.A. MicroRNA modulation of RNA-binding protein regulatory elements. RNA Biol 2006, 3(2):57-59.
153. Kim V.N., Nam J.W. Genomics of microRNA. Trends Genet 2006, 22(3):165-173.
154. Zeng Y. Principles of micro-RNA production and maturation. Oncogene 2006, 25(46):6156-6162.
155. Kim Y.K., Kim V.N. Processing of intronic microRNAs. EMBO J 2007, 26(3):775-783.
156. Prasanth K.V., Spector D.L. Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum. Genes Dev 2007, 21(1):11-42.
157. Rana T.M. Illuminating the silence. Understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007, 8(1):23-36.
158. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318(5858):1931-1934.
159. Perron M.P., Provost P. Protein interactions and complexes in human microRNA biogenesis and function. Front Biosci 2008, 13:2537-2547.
160. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331(6024):1153-1158.
161. Stephens P.J., Greenman C.D., Fu B., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144(1):27-40.
162. Cairns J. The origin of human cancers. Nature 1981, 289(5796):353-357.
163. Bogen K.T. Improved prediction of carcinogenic from mutagenic potencies for chemicals positive in rodents and the Ames test. Mol Environ Mutagen 1995, 25(1):37-49.
164. Fukushima T., Hamada Y., Yamada H., Horii I. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride - regulating role of micro-RNA for RNA expression. J Toxicol Sci 2007, 32(4):401-409.
165. Babar I.A., Slack F.J., Weidhaas J.B. MiRNA modulation of the cellular stress response. Future Oncol 2008, 4(2):289-298.
166. Simone N.L., Soule B.P., Ly D., Saleh A.D., Savage J.E., Degraff W., et al. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 2009, 4(7):e6377.
167. Detzer A., Engel C., Wünsche W., Sczakiel G. Cell stress is related to re-localization of Argonaute 2 and to decreased RNA interference in human cells. Nucl Acids Res 2011, 39(7):2727-2741.
168. Hatfield S.D., Shcherbata H.R., Fischer K.A., Nakahara K., Carthew R.W., Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005, 435(7044):974-978.
169. Shcherbata H.R., Hatfield S., Ward E.J., Reynolds S., Fischer K.A., Ruohola-Baker H. The microRNA pathway plays a regulatory role in stem cell division. Cell Cycle 2006, 5(2):172-175.
170. Foshay K.M., Gallicano G.I. Small RNAs, big potential: the role of MicroRNAs in stem cell function. Curr Stem Cell Res Ther 2007, 2(4):264-271.
171. Wang Y., Medvid R., Melton C., Jaenisch R., Blelloch R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet 2007, 39(3):380-385.
172. Hatfield S., Ruohola-Baker H. MicroRNA and stem cell function. Cell Tissue Res 2008, 331(1):57-66.
173. Sullivan G.F., Yang J.-M., Vassil A., Yang J., Bash-Babula, Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 2000, 105(9):1261-1267.
174. Day R.M., Suzuki Y.J. Cell proliferation, reactive oxygen and cellular glutathione. Dose-Response 2005, 3(3):425-442.
175. Filomeni G., Aquilano K., Rotilio G., Ciriolo M.R. Antiapoptotic response to induced GSH depletion: involvement of heat shock proteins and NF-kappaB activation. Antioxid Redox Signal 2005, 7(3-4):446-455.
176. Faraonio R., Vergara P., Di Marzo D., Pierantoni M.G., Napolitano M., Russo T., et al. P53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 2006, 281(52):39776-39778.
177. Vollrath V., Wielandt A.M., Iruretagoyena M., Chianale J. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J 2006, 395(3):599-609.
178. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Ann Rev Pharmacol Toxicol 2007, 47:89-116.
179. Yeh C.-T., Yen G.-C. Induction of hepatic antioxidant enzymes by phenolic acids in rats is accompanied by increased levels of multidrug resistance-associated Protein 3 mRNA expression. J Nutr 2006, 136(1):11-15.
180. Galli A., Svegliati-Baroni G., Ceni E., Milani S., Ridolfi F., Salzano R., et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005, 41(5):1074-1084.
181. Shah Y.M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F.J. Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 2007, 27(12):4238-4247.
182. Gu J., Iyer V.R. PI3K signaling and miRNA expression during the response of quiescent human fibroblasts to distinct proliferative stimuli. Genome Biol 2006, 7(5):R42.1-R42.15.
183. Shilo S., Roy S., Khanna S., Sen C.K. MicroRNA in cutaneous wound healing: a new program. DNA Cell Biol 2007, 26(4):227-237.
184. Bavan L., Midwood K., Nanchahal J. MicroRNA epigenetics: a new avenue for wound healing research. BioDrugs 2011, 25(1):27-41.
185. Gentile A., Comoglio P.M. Invasive growth: a genetic program. Int J Dev Biol 2004, 48(5-6):451-456.
186. Inui M., Martello G., Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010, 11(4):252-263.
187. Lujambio A., Calin G.A., Villanueva A., Ropero S., Montserrat Sánchez-Céspedese M., Blanco D., et al. A microRNA DNA methylation signature for human cancer metastasis. PNAS 2008, 105(36):13556-13561.
188. Cha S.T., Chen P.S., Johansson G., Chu C.Y., Wang M.Y., Jeng Y.M., et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010, 70(7):2675-2685.
189. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033.
190. Almeida A., Bolaños J.P., Moncada S. E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. PNAS USA 2010, 107(2):738-741.
191. Dang C.V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010, 70(3):859-862.
192. Najafov A., Alessi D.R. Uncoupling the Warburg effect from cancer. PNAS USA 2010, 107(45):19135-19136.
193. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005, 6(12):1191-1197.
194. Sonkoly E., Pivarcsi A. MicroRNAs in inflammation. Int Rev Immunol 2009, 28(6):535-561.
195. Recchiuti A., Krishnamoorthy S., Fredman G., Chiang N., Serhan C.N. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J 2011, 25(2):544-560.
196. DuBowski A., Johnston D.A., Rupp T., Beltran L., Conti C.J., DiGiovanni J. Papillomas at high risk for malignant progression arising both early and late during two-stage carcinogenesis in SENCAR mice. Carcinogenesis 1998, 19(6):1141-1147.
197. Darwiche N., Ryscavage A., Perez-Lorenzo R., Wright L., Bae D.-S., Hennings H., et al. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion: expression profiling high-risk benign skin lesions. Oncogene 2007, 26(48):6885-6895.
198. Glick A., Ryscavage A., Perez-Lorenzo R., Hennings H., Yuspa S., Darwiche N. The high-risk benign tumor: evidence from the two-stage skin cancer model and relevance for human cancer. Mol Carcinogenesis 2007, 46(8):605-610.
199. Li Y., Wheeler D.L., Ananthaswamy H.N., Verma A.K., Oberley T.D. Differential tumor biology effects of double-initiation in a mouse skin chemical carcinogenesis model comparing wild type versus protein kinase Cepsilon overexpression mice. Toxicol Pathol 2007, 35(7):942-951.
200. Mandinova A., Kolev V., Neel V., Hu B., Stonely W., Lieb J., et al. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest 2009, 119(10):3127-3137.
201. Markell M.L., Perez-Lorenzo R., Masiuk K.E., Kennett M.J., Glick A.B. Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression. Carcinogenesis 2010, 31(12):2127-2135.
202. Lapouge G., Youssef K.K., Vokaer B., Achouri Y., Michaux C., Sotiropoulou P.A., et al. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci USA 2011, 108(18):7431-7436.
203. Markell M.L., Masiuk K.E., Blazanin N., Glick A.B. Pharmacological inhibition of ALK5 causes selective induction of terminal differentiation in mouse keratinocytes expressing oncogenic HRAS. Mol Cancer Res 2011, 9(6):746-756.
204. Caligaris-Cappio F., Gobbi M., Bergui L., Campana D., Lauria F., Fierro M.T., et al. B-chronic lymphocytic leukaemia patients with stable benign disease show a distinctive membrane phenotype. Br J Haematol 1984, 56(4):655-660.
205. Gardner G.J., Birrer M.J. Ovarian tumors of low malignant potential: can molecular biology solve this enigma?. J Natl Cancer Inst 2001, 93(15):1122-1123.
206. Guess H.A. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001, 23(1):152-158.
207. Umeda Y., Arito H., Kano H., Ohnishi M., Matsumoto M., Nagano K., et al. Two-year study of carcinogenicity and chronic toxicity of biphenyl in rats. J Occup Health 2002, 44(3):176-183.
208. Gao J., Huang H.Y., Pak J., Cheng J., Zhang Z.T., Shapiro E., et al. P53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 2004, 23(3):687-696.
209. FV600E-induced lung tumors. Genes Dev 2007, 21(4):379-384.
210. Mak H.Y., Naba A., Varma S., Schick C., Day A., Sengupta S., et al. Ezrin phosphorylation on tyrosine 477 regulates invasion and metastasis of breast cancer cells. BMC Cancer 2012, 12(1):82. 10.1186/1471-2407-12-82.
211. Mäkinen N., Mehine M., Tolvanen J., Kaasinen E., Li Y., Lehtonen H.J., et al. MED12, the Mediator Complex Subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011, 334(6053):252-255.
212. Nessel C.S., Freeman J.J., Forgash R.C., McKee R.H. The role of dermal irritation in the skin tumor promoting activity of petroleum middle distillates. Toxicol Sci 1999, 49(1):48-55.
213. Woutersen R.A., van Garderen-Hoetmer A., Bruijntjes J.P., Zwart A., Feron V.J. Nasal tumours in rats after severe injury to the nasal mucosa and prolonged exposure to 10ppm formaldehyde. J Appl Toxicol 1989, 9(1):39-46.
214. Monticello T.M., Swenberg J.A., Gross E.A., Leininger J.R., Kimbell J.S., Seilkop S., et al. Correlation of regional and nonlinear formaldehyde-induced nasal cancer with proliferating populations of cells. Cancer Res 1996, 56(5):1012-1022.
215. Allen D.G., Pearse G., Haseman J.K., Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol 2004, 32(4):393-401.
216. Maronpot R.R., Yoshizawa K., Nyska A., Harada T., Flake G., Mueller G., et al. Hepatic enzyme induction: histopathology. Toxicol Pathol 2010, 38(5):776-795.
217. Campbell A.H., Lee E.J. The relationship between lung cancer and chronic bronchitis. Br J Dis Chest 1963, 57(3):113-119.
218. Schreiber H., Nettesheim P., Lijinsky W., Richter C.B., Walburg H.E. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitroheptamethyleneimine: enhancement by respiratory infection. J Natl Cancer Inst 1972, 49(4):1107-1114.
219. Nettesheim P., Topping D.C., Jamasbi R. Host and environmental factors enhancing carcinogenesis in the respiratory tract. Ann Rev Pharmacol Toxicol 1981, 21:133-163.
220. Littman A.J., Jackson L.A., Vaughan T.L. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005, 14(4):773-778.
221. Zhang H., García Rodríguez L.A., Hernández-Díaz S. Antibiotic use and the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(6):1308-1315.
222. Liang H.Y., Li X.L., Yu X.S., Guan P., Yin Z.H., He Q.C., et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer 2009, 125(12):2244-2936.
223. Hazelton W.D., Clements M.S., Moolgavkar S.H. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1171-1181.
224. Lee J.J., Liu D., Lee J.S., Kurie J.M., Khuri F.R., Ibarguen H., et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 2001, 93(14):1081-1088.
225. Luppi F., Aarbiou J., van Wetering S., Rahman I., de Boer W.I., Rabe K.F., et al. Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. Respir Res 2005, 6:140. 10.1186/1465-9921-6-140.
226. Nyunoya T., Monick M.M., Klingelhutz A., Yarovinsky T.O., Cagley J.R., Hunninghake G.W. Cigarette smoke induces cellular senescence. Am J Respir Cell Mol Biol 2006, 35(6):681-688.
227. Ramage L., Jones A.C., Whelan C.J. Induction of apoptosis with tobacco smoke and related products in A549 lung epithelial cells in vitro. J Inflamm (Lond) 2006, 3:3. 10.1186/1476-9255-3-3.
228. Tuder R.M., Yun J.H., Graham B.B. Cigarette smoke triggers code red: p21CIP1/WAF1/SDI1 switches on danger responses in the lung. Am J Respir Cell Mol Biol 2008, 39(1):1-6.
229. Johnson M.D., Schilz J., Djordjevic M.V., Rice J.R., Shields P.G. Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiol Biomarkers Prev 2009, 18(12):3263-3304.
230. Takahashi H., Ogata H., Nishigaki R., Broide D.H., Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010, 17(1):89-97.
231. Nuorti J.P., Butler J.C., Farley M.M., Harrison L.H., McGeer A., Kolczak M.S., et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000, 342(10):681-689.
232. Arcavi L., Benowitz N.L. Cigarette smoking and infection. Arch Intern Med 2004, 164(20):2206-2216.
233. Office of the Surgeon General. 2004. The health consequences of smoking: a report of the surgeon general. US centers for disease control and prevention, office on smoking and health, Atlanta, GA. pp. 428-447. http://www.ncbi.nlm.nih.gov/books/NBK44694/.
234. Lu K., Moeller B., Doyle-Eisele M., McDonald J., Swenberg J.A. Molecular dosimetry of N2-hydroxymethyl-dG DNA adducts in rats exposed to formaldehyde. Chem Res Toxicol 2011, 24(2):159-161.
235. Honma Y., Ushiki T., Takeda M., Chiba A., Oka S. Remarkable papillomas in white sturgeons, Acipenser transmontanus, reared in an aquarium. Ichthyol Res 1999, 46(2):107-114.
236. Dal Maso L., Zucchetto A., Tavani A., Montella M., Ramazzotti V., Polesel J., et al. Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 2006, 118(10):2632-2635.
237. Sekine I., Kawase Y., Ooi J., Matsumoto K., Ito M., Okumura Y., et al. Radiation-induced tumors - study based on biopsied and surgical materials. Acta Medica Nagasakiensia 1986, 31(1-4):232-241.
238. Gross L., Dreyfuss Y., Fraggiana T. Incidence and nature of tumors induced in Sprague-Dawley rats by γ-irradiation. Cancer Res 1988, 48(9):2451-2453.
239. Chen Y.-H., Keller J.J., Kang J.-H., Lin H.-C. Association between traumatic brain injury and the subsequent risk of brain cancer. J Neurotrauma 2012, 29(7):1328-1333.
240. Deelman H.T. The part played by injury and repair in the development of cancer, with remarks on the growth of experimental cancer. Br Med J 1927, 1:872-874.
241. Arwert E.N., Hoste E., Watt F.M. Epithelial stem cells, wound healing and cancer. Nat Rev Cancer 2012, 12:170-180.
242. Edwards J.E., Dalton A.J. Induction of cirrhosis of the liver and of hepatomas in mice with carbon tetrachloride. J Natl Cancer Inst 1942, 3:19-41.
243. Eschenbrenner A.B., Miller E. Liver necrosis and the induction of carbon tetrachloride hepatomas in strain A mice. J Natl Cancer Inst 1946, 6:325-341.
244. Hollander C.F., Bentvelzen P. Enhancement of urethan induction of hepatomas in mice by prior partial hepatectomy. J Natl Cancer Inst 1968, 41(6):1303-1306.
245. Newberne P.M., de Camargo J.L.V., Clark A.J. Choline deficiency, partial hepatectomy, and liver tumors in rats and mice. Toxicol Pathol 1982, 10:95-106.
246. Curry B., Ach R. Measurement and interpretation of microRNA expression profiles. MicroRNA profiling in cancer: a bioinformatics perspective 2009, 1-22. Pan Stanford Publishing, Singapore. Y. Gusev (Ed.).
247. Liu H., Brannon A.R., Reddy A.R., Alexe G., Seiler M.W., Arreola A., et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 2010, 4:51.
248. Rahbari R., Holloway A.K., He M., Khanafshar E., Clark O.H., Kebebew E. Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol 2011, 18(4):1158-1165.
249. Nilsson S, Landberg G. MicroRNA signature of columnar cell hyperplasia from patients with high risk of breast cancer. Cancer Res 2010;70(24 Suppl. 2). Abstract No. P3-09-06, doi:10.1158/0008-5472.SABCS10-P3-09-06.
250. Wang W., Corrigan-Cummins M., Hudson J., Maric I., Simakova O., Neelapu S.S., et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 2012, 97(4):586-594.
251. Leone V., D'Angelo D., Pallante P., Croce C.M., Fusco A. Thyrotropin regulates thyroid cell proliferation by up-regulating miR-23b and miR-29b that target SMAD3. J Clin Endocrinol Metab 2012, 97(9):3292-3301.
252. Snowdon J., Zhang X., Childs T., Tron V.A., Feilotter H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 2011, 6(8):e22828. 10.1371/journal.pone.0022828.
253. Olson P., Lu J., Zhang H., Shai A., Chun M.G., Wang Y., et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009, 23(18):2152-2165.
254. El Ouaamari A., Baroukh N., Martens G.A., Lebrun P., Pipeleers D., van Obberghen E. MiR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008, 57(10):2708-2717.
255. Walker M.D. Role of microRNA in pancreatic β-cells: where more is less. miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008, 57(10):2708-2717.
256. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67(13):6130-6135.
257. Joshi S.R., Comer B.S., McLendon J.M., Gerthoffer W.T. MicroRNA regulation of smooth muscle phenotype. Mol Cell Pharmacol 2012, 4(1):1-16.
258. Ichihara A., Jinnin M., Yamane K., Fujisawa A., Sakai K., Masuguchi S., et al. MicroRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br J Dermatol 2011, 165(5):1003-1010.
259. Xu N., Brodin P., Wei T., Meisgen F., Eidsmo L., Nagy N., et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011, 131(7):1521-1529.
260. Doupé D.P., Alcolea M.P., Roshan A., Zhang G., Klein A.M., Simons B.D., et al. A single progenitor population switches behavior to maintain and repair esophageal epithelium. Science 2012, 337:1091-1093.
261. Bader A.G. MiR-34 - a microRNA replacement therapy is headed to the clinic. Frontiers Genet 2012, 3:120. 10.3389/fgene.2012.00120.
262. Kasinski A.L., Slack F.J. MiRNA-34 prevents cancer initiation and progression in a therapeutically-resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012, 10.1158/0008-5472.CAN-12-2001.
263. Yamamura S., Saini S., Majid S., Hirata H., Ueno K., Deng G., et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012, 7(1):e29722.
264. Mazar J., Khaitan D., DeBlasio D., Zhong C., Govindarajan S.S., Kopanathi S., et al. Epigenetic regulation of microrna genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One 2011, 6(9):e24922. 10.1371/journal.pone.0024922.
265. Benditt E.P., Benditt J.M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973, 70(6):1753-1756.
266. Schwartz S.M., Murry C.E. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 1998, 49:437-460.
267. Schmeck B., Beermann W., N'Guessan P.D., Hocke A.C., Opitz B., Eitel J., et al. Simvastatin reduces Chlamydophila pneumoniae-mediated histone modifications and gene expression in cultured human endothelial cells. Circ Res 2008, 102(8):888-895.
268. Deniset J.F., Cheung P.K., Dibrov E., Lee K., Steigerwald S., Pierce G.N. Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response. Am J Pathol 2010, 176(2):1028-1037.
269. Iriz E., Cirak M.Y., Engin E.D., Zor M.H., Erer D., Ozdogan M.E., et al. Detection of Helicobacter pylori DNA in aortic and left internal mammary artery biopsies. Tex Heart Inst J 2008, 35(2):130-135.
270. Aydemir S., Eren H., Tekin I.O., Harmandar F.A., Demircan N., Cabuk M. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm 2010, 2010:685903. 10.1155/2010/685903.
271. Suarez F., Lortholary O., Hermine O., Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006, 107(8):3034-3044.
272. Takei T., Rivas-Gotz C., Delling C.A., Koo J.T., Mills I., McCarthy T.L., et al. Effect of strain on human keratinocytes in vitro. J Cell Physiol 1997, 173(1):64-72.
273. Yano S., Komine M., Fujimoto M., Okochi H., Tamaki K. Mechanical stretching in vitro regulates signal transduction pathways and cellular proliferation in human epidermal keratinocytes. J Invest Dermatol 2004, 122(3):783-790.
274. Renò F., Traina V., Cannas M. Mechanical stretching modulates growth direction and MMP-9 release in human keratinocyte monolayer. Cell Adhes Migr 2009, 3(3):239-242.
275. Glantschnig H., Varga F., Rumpler M., Klaushofer K. Prostacyclin (PGI2): a potential mediator of c-fos expression induced by hydrostatic pressure in osteoblastic cells. Eur J Clin Invest 1996, 26(7):544-548.
276. Cheng M.Z., Rawlinson S.C., Pitsillides A.A., Zaman G., Mohan S., Baylink D.J., et al. Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res 2002, 17(4):593-602.
277. Luna C., Li G., Qiu J., Epstein D.L., Gonzalez P. MicroRNA-24 regulates the processing of latent TGFβ1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol 2011, 226(5):1407-1414.
278. Lu S., Sun Y.H., Shi R., Clark C., Li L., Chiang V.L. Novel and mechanical stress-responsive MicroRNAs in Populus trichocarpa that are absent from Arabidopsis. Plant Cell 2005, 17(8):2186-2203.
279. Lu S. MicroRNAs and mechanical stress. Mech Integration Plant Cells Plants: Signal Commun Plants 2011, 9:329-344.